- Home
- SPRO vs LTRN Comparison
SPRO vs LTRN Comparison
Compare SPRO & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- LTRN
- Stock Information
- Founded
- SPRO 2013
- LTRN 2013
- Country
- SPRO United States
- LTRN United States
- Employees
- SPRO N/A
- LTRN N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- LTRN Health Care
- Exchange
- SPRO Nasdaq
- LTRN Nasdaq
- Market Cap
- SPRO 33.0M
- LTRN 36.1M
- IPO Year
- SPRO 2017
- LTRN 2020
- Fundamental
- Price
- SPRO $2.50
- LTRN $3.05
- Analyst Decision
- SPRO Buy
- LTRN Strong Buy
- Analyst Count
- SPRO 4
- LTRN 1
- Target Price
- SPRO $5.00
- LTRN $25.00
- AVG Volume (30 Days)
- SPRO 10.8M
- LTRN 71.9K
- Earning Date
- SPRO 05-13-2025
- LTRN 05-15-2025
- Dividend Yield
- SPRO N/A
- LTRN N/A
- EPS Growth
- SPRO N/A
- LTRN N/A
- EPS
- SPRO N/A
- LTRN N/A
- Revenue
- SPRO $44,584,000.00
- LTRN N/A
- Revenue This Year
- SPRO N/A
- LTRN N/A
- Revenue Next Year
- SPRO N/A
- LTRN N/A
- P/E Ratio
- SPRO N/A
- LTRN N/A
- Revenue Growth
- SPRO N/A
- LTRN N/A
- 52 Week Low
- SPRO $0.51
- LTRN $2.55
- 52 Week High
- SPRO $2.80
- LTRN $6.40
- Technical
- Relative Strength Index (RSI)
- SPRO 86.18
- LTRN 40.80
- Support Level
- SPRO $0.66
- LTRN $2.85
- Resistance Level
- SPRO $2.48
- LTRN $3.23
- Average True Range (ATR)
- SPRO 0.13
- LTRN 0.38
- MACD
- SPRO 0.20
- LTRN -0.09
- Stochastic Oscillator
- SPRO 86.36
- LTRN 12.41
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.